OUR TESTS
Breast Cancer Testing & Genomics
What’s driving the growth of my patient’s breast cancer?
Interrogating 80 genes, the BluePrint® test identifies the underlying biology of an individual breast cancer. The tumor is then accurately classified as one of three subtypes, which reveal valuable information about its behavior, long-term prognosis and response to systemic therapy. Results are typically available in <6 days, just in time for your pre-operative consultation.1,2
Breast Cancer Biology
Explore BluePrint Molecular Subtypes
Luminal-Type
- Driven primarily by estrogen and progesterone hormone pathways
- Stratified by MammaPrint into Luminal A-Type and Luminal B-Type
- Luminal A-Type is associated with Low Risk
- Luminal B-Type is associated with High Risk
- Distinct outcomes support more informed treatment planning
HER2-Type
- Driven primarily by the HER2 pathway
- May not always align with IHC- or FISH-derived HER2 results
- Often responds well to HER2-targeted therapies in the neoadjuvant setting
- HER2-targeted agents are associated with good long-term outcomes
Basal-Type
- Not driven by ER, PR, or HER2 pathways
- Acts more like triple-negative breast cancer clinically
- More aggressive subtype that may benefit from standard or novel TNBC regimens
- Select patients may benefit from neoadjuvant treatment
I am a strong believer in treating a patient’s breast cancer according to the subtype of their cancer. We should not treat all breast cancers the same.
– Dr. Peter Beitsch, MD
Determine the underlying pathways driving the growth of a tumor
BluePrint is an 80-gene molecular subtyping test that goes beyond IHC and FISH to reveal the underlying pathways behind a tumor’s growth at the earliest stage possible in a woman’s breast cancer care journey to optimize and personalize treatment planning. BluePrint further stratifies 23% of tumors into a different molecular subtype compared with IHC/FISH, identifying an opportunity to personalize treatment to the patient’s molecular profile.5
Genomic Subtyping That Guides Personalized Treatment
ER+/BASAL PATIENTS ARE
BluePrint Basal-Type
MAMMAPRINT HIGH RISK
Clinically, these patients appear to have less aggressive tumors but the underlying biology indicates they will act like triple negative breast cancer.2 Treating ER+/Basal patients more aggressively may improve their outcomes.
ER+, HER2+/LUMINAL PATIENTS ARE
BluePrint/Luminal-Type
MAMMAPRINT HIGH RISK
Nearly 50% of pathologically HER2+ patients are reclassified to a Luminal molecular subtype. ER+, HER2+/Luminal patients do not respond as well to treatment with HER2-targeted agents as those who have concordant clinical and molecular HER2 subtypes.3
In the NBRST study, 22% of patients were reclassified from their original clinical or pathologic subtype into a different molecular subtype identifying an opportunity to personalize treatment to the patient’s molecular profile.4
NEW BLUEPRINT DATA
New BluePrint Publications & Data
BluePrint FAQ
1. BluePrint is a laboratory-developed test that was developed, validated and is performed exclusively by Agendia. The test is intended for clinical purposes. The test has not been cleared by the U.S. Food and Drug Administration (FDA) but has been CE-marked for use in Europe. The laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) to ensure the quality and validity of the tests. Our laboratories are CAP-accredited and certified under CLIA to perform high complexity clinical laboratory testing. (Agendia is committed to delivering results in less than 10 business days, and results are provided within 6 business days for the majority of cases)
2. Groenendijk FH, et al. NPJ Breast Cancer. 2019;5:15.
3. Rong P et. al. Cancer Res 2018;78(13 Suppl):Abstract nr 2612.
4. Whitworth, et al. Ann Surg Oncol (2017) 24:669–675
5. Whitworth, P., et al. Ann Surg Oncol (2022) 29:4141–4152
6. Whitworth et al., JCO Precis Oncol. 2022 Apr; 6(1): e2100463
7. Genes Chromosomes Cancer. 2021 Dec 11;61(3):148–160. doi: 10.1002/gcc.23014
The MammaPrint + BluePrint Test Suite
The potential to go even deeper. To treat even more effectively.
With the combined insights of MammaPrint and BluePrint alongside clinical factors, physicians gain a more comprehensive basis for predicting prognosis and the benefit of specific treatments.
MammaPrint enables us to further divide luminal tumors into two subtypes that align with the test’s binary results.
